2-(5-methyl-thiazol-2-yl)-isoindole-1,3-dione | 832091-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(5-methyl-thiazol-2-yl)-isoindole-1,3-dione
• 英文别名: 2-(5-methylthiazol-2-yl)isoindoline-1,3-dione；2-(5-methyl-1,3-thiazol-2-yl)isoindole-1,3-dione
• CAS: 832091-87-9
• 化学式: C₁₂H₈N₂O₂S
• 分子量: 244.274
• InChiKey: AMHZPAKRQGUVCK-UHFFFAOYSA-N

物化性质

• 熔点：
  173-175 °C
• 沸点：
  474.3±38.0 °C(Predicted)
• 密度：
  1.473±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  78.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(5-methyl-thiazol-2-yl)-isoindole-1,3-dione 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 为溶剂， 以75%的产率得到2-(4-bromo-5-methylthiazol-2-yl)isoindoline-1,3-dione
  参考文献：
  名称：

  [EN] THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY
  [FR] THIAZOLOPYRIMIDINONES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR NMDA

  摘要：

  本发明涉及某些噻唑吡咯嘧啶酮化合物，用于调节NMDA受体活性，包括这些化合物的药物组合物以及治疗神经和精神疾病的方法。

  公开号：

  WO2015052226A1
• 作为产物：
  描述：

  2-氨基-5-甲基噻唑 、 苯酐 以 1,4-二氧六环 为溶剂， 以56%的产率得到2-(5-methyl-thiazol-2-yl)-isoindole-1,3-dione
  参考文献：
  名称：

  [EN] THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY
  [FR] THIAZOLOPYRIMIDINONES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR NMDA

  摘要：

  本发明涉及某些噻唑吡咯嘧啶酮化合物，用于调节NMDA受体活性，包括这些化合物的药物组合物以及治疗神经和精神疾病的方法。

  公开号：

  WO2015052226A1

文献信息

• THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20160222033A1

  公开（公告）日：2016-08-04

  The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些噻唑嘧啶酮化合物、包含该类化合物的制药组合物以及使用该类化合物的治疗方法。
• Thiazolopyrimidinones and methods of use thereof
  申请人：Genentech, Inc.

  公开号：US10647731B2

  公开（公告）日：2020-05-12

  The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些噻唑并嘧啶酮化合物、包含此类化合物的药物组合物以及使用此类化合物进行治疗的方法。
• Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells
  作者：Chao-Bin Yeh、Chi-Jung Su、Jin-Ming Hwang、Ming-Chih Chou

  DOI：10.1016/j.ejmech.2010.05.053

  日期：2010.9

  Previous research indicates that cantharidin, norcantharidin and their analogues exhibit anticancer activity due to their inhibition of cancer cell lines such as HL60, HT29 and L1210. The anticancer activities of cantharidin, norcantharidin and their analogues involve the suppression of serine/threonine protein phosphatases (PPs) activity. However, cantharidin is not suitable for cancer therapy because of its high cytotoxicity in vitro (IC(50) = 21 mu M in primary cultured rat hepatocytes). In this study, synthetic cantharidin analogues with a structure of aminothiazole compounds 3-9 and a structure of anhydride compounds 10-12 were screened for anticancer activities and cytotoxic effects on human hepatocellular carcinoma cell (HCC) lines HepG2, Sk-Hep1, and primary cultured rat hepatocytes. Experimental results indicated that compounds 3-9 did not perform as expected with regard to anticancer activity and exhibited lower cytotoxicity. Compound 10 promoted apoptosis in HepG2 (IC(50) = 62 mu M) and SK-Hep1 (IC(50) = 151 mu M) cell lines. Compounds 11 and 12 had anticancer potential similar to that of compound 10. After treatment with compounds 3-12, primary cultured rat hepatocytes exhibited no cytotoxicity (IC(50) > 200 mu M). By investigating the structure activity relationship (SAR) of these analogues as a whole, this study suggests that the anhydride ether oxygen such as in cantharidin, norcantharidin and compounds 10-12 may be correlated with HCC survival suppression. The results further suggest that the elimination of bridging ether oxygen on the ring, such as in compounds 10-12, can decrease cytotoxicity. (C) 2010 Elsevier Masson SAS. All rights reserved.
• THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3055315B1

  公开（公告）日：2018-07-25
• US9988400B2
  申请人：——

  公开号：US9988400B2

  公开（公告）日：2018-06-05